On Monday, Veeva Systems Cl A got a positive adjustment to its Relative Strength (RS) Rating, from 70 to 81.
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Veeva Systems Cl A is now considered extended and out of buy range after clearing a 226.47 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 31% earnings growth in the latest quarterly report, while sales growth came in at 13%.
Veeva Systems Cl A holds the No. 2 rank among its peers in the Computer Software-Medical industry group. Doximity is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
